Close
Company Search
Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Astrazeneca (AZN) Share Price

Price 13,592.00p on 02-01-2026 at 19:40:05
Change -198.00p -1.44%
Buy 13,632.00p
Sell 13,626.00p
Add to Watchlist
Add to Portfolio
Add to Quickpicks
Last Trade: Unknown 7.00 at 13,657.3668p
Day's Volume: 3,980,211
Last Close: 13,592.00p
Open: 13,722.00p
ISIN: GB0009895292
Day's Range 13,592.00p - 13,916.00p
52wk Range: 9,574.00p - 14,206.00p
Market Capitalisation: £210.71b
VWAP: 13,713.04595p
Shares in Issue: 1.55b

Sector: Medicine and Biotech

Listed In: FTSE All-Share, FTSE All-Share ex Investment Trusts, FTSE Lower Yield, FTSE 350 ex Investment Trusts, FTSE 350 , FTSE 100,

Astrazeneca (AZN) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Unknown* 7 13,657.3668p SI Trade
Currency Conversion
Negotiated Trade
 16:49:48 - 02-Jan-26
Sell* 56 13,592.00p SI Trade
Suspected SELL Trade
 16:49:48 - 02-Jan-26
Sell* 186 13,592.00p SI Trade
 16:49:35 - 02-Jan-26
Buy* 2,151 13,713.588p SI Trade
Negotiated Trade
 16:47:00 - 02-Jan-26
Unknown* 2,151 13,746.20918p SI Trade
Currency Conversion
Negotiated Trade
 16:47:00 - 02-Jan-26
Sell* 37 13,592.00p SI Trade
 16:39:02 - 02-Jan-26
Sell* 34 13,592.00p Automatic Execution
 16:35:58 - 02-Jan-26
Sell* 200 13,592.00p Automatic Execution
 16:35:08 - 02-Jan-26
Sell* 33 13,592.00p SI Trade
 16:35:04 - 02-Jan-26
Sell* 16 13,592.00p SI Trade
 16:35:04 - 02-Jan-26
See more Astrazeneca trades

Astrazeneca (AZN) Share Price History

Time period:
to
Date Open High Low Close Volume
2nd Jan 2026 (Fri) 13,722.00 13,916.00 13,592.00 13,592.00 3,980,211
1st Jan 2026 (Thu) 13,790.00 13,790.00 13,790.00 13,790.00 0
31st Dec 2025 (Wed) 13,768.00 13,844.00 13,722.00 13,790.00 393,700
30th Dec 2025 (Tue) 13,712.00 13,798.00 13,696.00 13,750.00 950,185
29th Dec 2025 (Mon) 13,736.00 13,806.00 13,680.00 13,748.00 1,490,186
26th Dec 2025 (Fri) 13,674.00 13,674.00 13,674.00 13,674.00 0
25th Dec 2025 (Thu) 13,674.00 13,674.00 13,674.00 13,674.00 0
24th Dec 2025 (Wed) 13,742.00 13,742.00 13,612.00 13,674.00 688,169
23rd Dec 2025 (Tue) 13,612.00 13,806.00 13,604.00 13,736.00 1,082,889
22nd Dec 2025 (Mon) 13,592.00 13,632.00 13,476.00 13,632.00 1,451,074
19th Dec 2025 (Fri) 13,574.00 13,714.00 13,508.00 13,672.00 10,404,455
18th Dec 2025 (Thu) 13,500.00 13,594.00 13,376.00 13,548.00 4,515,814
17th Dec 2025 (Wed) 13,574.00 13,682.00 13,534.00 13,554.00 2,468,738
16th Dec 2025 (Tue) 13,744.00 13,836.00 13,448.00 13,506.00 3,264,005
15th Dec 2025 (Mon) 13,412.00 13,638.00 13,376.00 13,612.00 2,467,612
12th Dec 2025 (Fri) 13,502.00 13,536.00 13,362.00 13,444.00 1,443,553
11th Dec 2025 (Thu) 13,618.00 13,686.00 13,488.00 13,596.00 1,284,513
10th Dec 2025 (Wed) 13,482.00 13,848.00 13,472.00 13,514.00 2,485,716
9th Dec 2025 (Tue) 13,758.00 13,794.00 13,568.00 13,592.00 1,232,388
8th Dec 2025 (Mon) 13,580.00 13,702.00 13,478.00 13,578.00 3,939,445
5th Dec 2025 (Fri) 13,560.00 13,688.00 13,542.00 13,592.00 1,500,908
4th Dec 2025 (Thu) 13,612.00 13,660.00 13,452.00 13,514.00 1,868,284
See more Astrazeneca price history

Astrazeneca (AZN) Regulatory News

Date Source Headline
2nd Jan 2026 3:00 pm RNS Total Voting Rights
22nd Dec 2025 11:00 am RNS Director/PDMR Shareholding
22nd Dec 2025 11:00 am RNS Director/PDMR Shareholding
22nd Dec 2025 7:30 am RNS Enhertu granted BTD for post-neoadjuvant early BC
22nd Dec 2025 7:30 am RNS Enhertu granted BTD for post-neoadjuvant early BC
22nd Dec 2025 7:00 am RNS Update on LATIFY Phase III trial of ceralasertib
22nd Dec 2025 7:00 am RNS Update on LATIFY Phase III trial of ceralasertib
19th Dec 2025 11:00 am RNS Director/PDMR Shareholding
19th Dec 2025 11:00 am RNS Director/PDMR Shareholding
16th Dec 2025 7:05 am RNS Subcutaneous Saphnelo approved in EU
See more Astrazeneca regulatory news

Astrazeneca (AZN) Share News

Hutchmed savolitinib NDA for gastric cancer accepted in China

30th Dec 2025 11:21

(Alliance News) - Hutchmed China Ltd on Tuesday said Chinese regulators have accepted and granted priority review to its new drug application for savolitinib to treat certain patients with advanced gastric cancer, marking another regulatory step forward for the targeted therapy. Read More

LONDON MARKET CLOSE: FTSE fails to sparkle in tame pre-holiday trade

24th Dec 2025 13:14

(Alliance News) - The FTSE 100 drifted lower on Wednesday in lacklustre trading ahead of the Christmas break, although a chunky disposal by BP brought some life to proceedings. Read More

LONDON MARKET OPEN: FTSE mixed in shortened Christmas Eve trade

24th Dec 2025 09:17

(Alliance News) - Stock prices in London opened modestly lower on Wednesday, during a shortened trading session ahead of the Christmas holiday break. Read More

AstraZeneca says lung cancer trial fails to meet survival target

22nd Dec 2025 09:11

(Alliance News) - AstraZeneca PLC on Monday said a phase three trial in a potential treatment for a form of non-small cell lung cancer failed to meet a key aim, while its early breast cancer drug has been granted a breakthrough therapy designation in the US. Read More

LONDON BRIEFING: Harbour Energy makes USD3.2 billion US buy

22nd Dec 2025 07:52

(Alliance News) - Harbour Energy has struck a deal to deliver on a "long-standing ambition", while AstraZeneca reports a drug failed to meet its primary endpoint in a phase three trial, while another got breakthrough therapy designation in the US. Read More

See more Astrazeneca news
FTSE 100 Latest
Value9,951.14
Change19.76

Login to your account

Forgot Password?

Not Registered